{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:08:11Z","timestamp":1790028491255,"version":"4.0.1"},"reference-count":86,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.kint.2026.01.036","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T16:18:28Z","timestamp":1774023508000},"page":"1125-1136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cancer therapy and the kidney"],"prefix":"10.1016","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6249-9837","authenticated-orcid":false,"given":"Hassan","family":"Izzedine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Perazella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna Mohita","family":"Kuruvada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1578-0524","authenticated-orcid":false,"given":"Kenar D.","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2026.01.036_bib1","first-page":"500","article-title":"Acute kidney injury in patients with cancer","volume":"377","author":"Rosner","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.01.036_bib2","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/cam4.2140","article-title":"Acute kidney injury predicts all-cause mortality in patients with cancer","volume":"8","author":"Kang","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.kint.2026.01.036_bib3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1681\/ASN.2004100843","article-title":"Renal failure associated with cancer and its treatment: an update","volume":"16","author":"Humphreys","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.01.036_bib4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/ki.2012.484","article-title":"Glomerular diseases seen with cancer and chemotherapy: a narrative review","volume":"84","author":"Jhaveri","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.01.036_bib5","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/ki.2015.30","article-title":"New drug toxicities in the onco-nephrology world","volume":"87","author":"Perazella","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.01.036_bib6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.ackd.2013.08.003","article-title":"Glomerular diseases associated with cancer, chemotherapy, and hematopoietic stem cell transplantation","volume":"21","author":"Jhaveri","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.kint.2026.01.036_bib7","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/ki.2013.50","article-title":"Nephrology Crossword: onco-nephrology\u2014chemotherapy agents and nephrotoxicity","volume":"84","author":"Jhaveri","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.01.036_bib8","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.2215\/CJN.02780312","article-title":"Onco-nephrology: renal toxicities of chemotherapeutic agents","volume":"7","author":"Perazella","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.01.036_bib9","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2215\/CJN.0000000000000508","article-title":"Assessment of GFR in patients with cancer: a statement from the American Society of Onco-Nephrology","volume":"19","author":"Kitchlu","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.01.036_bib10","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1161\/HYP.0000000000000224","article-title":"Cancer therapy-related hypertension: a scientific statement from the American Heart Association","volume":"80","author":"Cohen","year":"2023","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2026.01.036_bib11","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1001\/jama.291.20.2441","article-title":"Prognostic importance of comorbidity in a hospital-based cancer registry","volume":"291","author":"Piccirillo","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2026.01.036_bib12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41371-023-00825-x","article-title":"Preexisting hypertension and cancer therapy: evidence, pathophysiology, and management recommendation","volume":"37","author":"Koskina","year":"2023","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.kint.2026.01.036_bib13","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","article-title":"Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer","volume":"25","author":"Pinder","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.kint.2026.01.036_bib14","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/1078155214567162","article-title":"Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: an observational single-centre study","volume":"22","author":"Gunaldi","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.kint.2026.01.036_bib15","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdp025","article-title":"Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis","volume":"20","author":"Di Lorenzo","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.kint.2026.01.036_bib16","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jacc.2015.07.025","article-title":"Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors","volume":"66","author":"Li","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.kint.2026.01.036_bib17","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1158\/1078-0432.CCR-09-0058","article-title":"Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment","volume":"15","author":"Maitland","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.kint.2026.01.036_bib18","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.ekir.2024.03.005","article-title":"Risk factors for severe hypertension and proteinuria after treatment with vascular endothelial growth factor signaling pathway inhibitors among patients with cancer","volume":"9","author":"Hanna","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.01.036_bib19","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kint.2026.01.036_bib20","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1200\/JCO.22.01875","article-title":"Onco-hypertension: changing paradigm of treating hypertension in patients with cancer","volume":"41","author":"Sahni","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.kint.2026.01.036_bib21","first-page":"281","article-title":"Cardiorenal impact of anti-cancer agents: the intersection of onco-nephrology and cardio-oncology","volume":"14","author":"Attieh","year":"2024","journal-title":"Cardiorenal Med"},{"key":"10.1016\/j.kint.2026.01.036_bib22","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","article-title":"VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management","volume":"46","author":"Izzedine","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.kint.2026.01.036_bib23","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s10147-024-02474-7","article-title":"Proteinuria frequency and subsequent renal dysfunction in bevacizumab-treated patients: a single center, retrospective, observational study","volume":"29","author":"Kataoka","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.kint.2026.01.036_bib24","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/ki.2011.288","article-title":"Proteinuria and hypertension with tyrosine kinase inhibitors","volume":"80","author":"Kandula","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.01.036_bib25","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/s12885-022-09611-3","article-title":"Decision making for anti-VEGF inhibitor continuation: dip stick? or urine protein\/creatinine ratio? (VERSiON UP study)","volume":"22","author":"Nakamura","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.kint.2026.01.036_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104609","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update","volume":"152","author":"Roskoski","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.kint.2026.01.036_bib27","doi-asserted-by":"crossref","first-page":"807","DOI":"10.5301\/jn.5000307","article-title":"Proteinuria and VEGF-targeted therapies: an underestimated toxicity?","volume":"26","author":"Izzedine","year":"2013","journal-title":"J Nephrol"},{"key":"10.1016\/j.kint.2026.01.036_bib28","doi-asserted-by":"crossref","first-page":"889","DOI":"10.21873\/anticanres.16882","article-title":"Efficacy and safety of anti-angiogenic agents for cancer patients with proteinuria or a history of proteinuria: a systematic review","volume":"44","author":"Kato","year":"2024","journal-title":"Anticancer Res"},{"key":"10.1016\/j.kint.2026.01.036_bib29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2215\/CJN.05610522","article-title":"How I manage hypertension and proteinuria associated with VEGF inhibitor","volume":"18","author":"Rashidi","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.01.036_bib30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/2399369319887979","article-title":"Thrombotic microangiopathy in dasatinib-treated patients with chronic myeloid leukemia","volume":"4","author":"Koshida","year":"2020","journal-title":"J Onco-Nephrol"},{"key":"10.1016\/j.kint.2026.01.036_bib31","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1093\/ndt\/gfaf091","article-title":"Complement activation in secondary thrombotic microangiopathies","volume":"40","author":"Morelle","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.01.036_bib32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.thromres.2023.02.012","article-title":"Eculizumab in the management of drug-induced thrombotic microangiopathy: a scoping review of the literature","volume":"224","author":"Zafar","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.kint.2026.01.036_bib33","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s12882-021-02470-3","article-title":"Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre","volume":"22","author":"Grall","year":"2021","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2026.01.036_bib34","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.kint.2024.09.017","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated nephrotoxicity: a position statement from the American Society of Onco-nephrology","volume":"107","author":"Herrmann","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.01.036_bib35","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejphar.2016.02.064","article-title":"Electrolyte disorders associated with the use of anticancer drugs","volume":"777","author":"Liamis","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.kint.2026.01.036_bib36","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3389\/fonc.2020.00779","article-title":"Electrolyte disorders induced by antineoplastic drugs","volume":"10","author":"Verzicco","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.kint.2026.01.036_bib37","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.xkme.2021.06.011","article-title":"Collapsing focal segmental glomerulosclerosis and acute kidney injury associated with chimeric antigen receptor T-cell therapy: a case report","volume":"3","author":"Acharya","year":"2021","journal-title":"Kidney Med"},{"key":"10.1016\/j.kint.2026.01.036_bib38","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.01.036_bib39","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1001\/jamaoncol.2019.0086","article-title":"Treatment-related complications of systemic therapy and radiotherapy","volume":"5","author":"Jairam","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.kint.2026.01.036_bib40","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jcrc.2011.06.014","article-title":"Critically ill patients with cancer and sepsis: clinical course and prognostic factors","volume":"27","author":"Rosolem","year":"2012","journal-title":"J Crit Care"},{"key":"10.1016\/j.kint.2026.01.036_bib41","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/ndt\/gfh637","article-title":"Outcome in critically ill medical patients treated with renal replacement therapy for acute renal failure: comparison between patients with and those without haematological malignancies","volume":"20","author":"Benoit","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.01.036_bib42","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.semnephrol.2010.09.009","article-title":"Acute kidney injury in hematopoietic cell transplantation","volume":"30","author":"Kogon","year":"2010","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.kint.2026.01.036_bib43","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2215\/CJN.02050309","article-title":"Renal vulnerability to drug toxicity","volume":"4","author":"Perazella","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.01.036_bib44","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2215\/CJN.03530412","article-title":"Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center","volume":"8","author":"Salahudeen","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.01.036_bib45","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ejim.2011.05.005","article-title":"Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study","volume":"22","author":"Christiansen","year":"2011","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.kint.2026.01.036_bib46","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000329042","article-title":"Predicting hospital mortality in critically ill cancer patients according to acute kidney injury severity","volume":"80","author":"Lib\u00f3rio","year":"2011","journal-title":"Oncology"},{"key":"10.1016\/j.kint.2026.01.036_bib47","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ackd.2013.06.010","article-title":"Tubulointerstitial injury associated with chemotherapeutic agents","volume":"21","author":"Shirali","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.kint.2026.01.036_bib48","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1053\/j.ajkd.2015.02.340","article-title":"Thrombotic microangiopathy, cancer, and cancer drugs","volume":"66","author":"Izzedine","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.01.036_bib49","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MD.0000000000000207","article-title":"Kidney diseases associated with antivascular endothelial growth factor (VEGF): an 8-year observational study at a single center","volume":"93","author":"Izzedine","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.kint.2026.01.036_bib50","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/jamaoncol.2015.1713","article-title":"Nephrotoxicity of the BRAF inhibitors vemurafenib and dabrafenib","volume":"1","author":"Jhaveri","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.kint.2026.01.036_bib51","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/ckj\/sfac062","article-title":"Anaplastic lymphoma kinase inhibitors and their effect on the kidney","volume":"15","author":"Bonilla","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2026.01.036_bib52","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2215\/CJN.07311009","article-title":"Treatment with IFN-\u03b1, -\u03b2, or -\u03b3 is associated with collapsing focal segmental glomerulosclerosis","volume":"5","author":"Markowitz","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11 suppl 13","key":"10.1016\/j.kint.2026.01.036_bib53","first-page":"11","article-title":"Managing toxicities of high-dose interleukin-2","volume":"16","author":"Schwartz","year":"2002","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.kint.2026.01.036_bib54","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/j.ajkd.2019.10.011","article-title":"Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma","volume":"76","author":"Gupta","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.01.036_bib55","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1681\/ASN.V1261164","article-title":"Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate","volume":"12","author":"Markowitz","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.01.036_bib56","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1172\/JCI44774","article-title":"Role of mTOR in podocyte function and diabetic nephropathy in humans and mice","volume":"121","author":"G\u00f6del","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2026.01.036_bib57","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-235083","article-title":"Severe hypophosphataemia following oral bisphosphonate treatment in a patient with osteoporosis","volume":"13","author":"Bagger","year":"2020","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.kint.2026.01.036_bib58","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.eururo.2022.05.025","article-title":"Extensive 177Lu-PSMA radioligand therapy can lead to radiation nephropathy with a renal thrombotic microangiopathy-like picture","volume":"83","author":"Sch\u00e4fer","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.kint.2026.01.036_bib59","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/cc4907","article-title":"Clinical review: specific aspects of acute renal failure in cancer patients","volume":"10","author":"Darmon","year":"2006","journal-title":"Crit Care"},{"key":"10.1016\/j.kint.2026.01.036_bib60","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/nrneph.2015.15","article-title":"Renal effects of targeted anticancer therapies","volume":"11","author":"Porta","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2026.01.036_bib61","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.semnephrol.2010.09.005","article-title":"Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention\/therapy","volume":"30","author":"Perazella","year":"2010","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.kint.2026.01.036_bib62","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients","volume":"68","author":"Shirali","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.01.036_bib63","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5414\/CNP71130","article-title":"Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution","volume":"71","author":"Glezerman","year":"2009","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.kint.2026.01.036_bib64","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.2215\/CJN.00860115","article-title":"Drug-induced glomerular disease: direct cellular injury","volume":"10","author":"Markowitz","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.01.036_bib65","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1001\/jamaoncol.2025.0756","article-title":"Intravenous magnesium and cisplatin-associated acute kidney injury","volume":"11","author":"Gupta","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.kint.2026.01.036_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100351","article-title":"Preloading magnesium attenuates cisplatin-associated nephrotoxicity: pilot randomized controlled trial (PRAGMATIC study)","volume":"7","author":"Suppadungsuk","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.kint.2026.01.036_bib67","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1093\/ndt\/gfn503","article-title":"Severe acute renal failure following high dose methotrexate therapy in adults with haematological malignancies: a significant number result from unrecognized co-administration of several drugs","volume":"23","author":"de Miguel","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.01.036_bib68","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/S0272-6386(96)90384-4","article-title":"Effective clearance of methotrexate using high-flux hemodialysis membranes","volume":"28","author":"Wall","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.01.036_bib69","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/phar.1360","article-title":"Efficacy of glucarpidase (carboxypeptidase G2) in patients with acute kidney injury after high-dose methotrexate therapy","volume":"34","author":"Widemann","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.kint.2026.01.036_bib70","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1182\/blood.2024026211","article-title":"Glucarpidase for treatment of high-dose methotrexate toxicity","volume":"145","author":"Gupta","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.kint.2026.01.036_bib71","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.amjmed.2008.11.025","article-title":"Renal effects of anti-angiogenesis therapy: update for the internist","volume":"122","author":"Gurevich","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.kint.2026.01.036_bib72","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/ckj\/sfv149","article-title":"Renal effects of BRAF inhibitors: a systematic review by the Cancer and the Kidney International Network","volume":"9","author":"Wanchoo","year":"2016","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2026.01.036_bib73","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00280-016-3086-7","article-title":"New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma","volume":"78","author":"Teuma","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.kint.2026.01.036_bib74","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5301\/jo-n.5000012","article-title":"Crizotinib: renal safety evaluation","volume":"1","author":"Perazella","year":"2017","journal-title":"J Onco-Nephrol"},{"key":"10.1016\/j.kint.2026.01.036_bib75","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.ekir.2020.11.029","article-title":"Acute tubular injury and renal arterial myocyte vacuolization following crizotinib administration","volume":"6","author":"Izzedine","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.01.036_bib76","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/cam4.437","article-title":"Complex renal cysts associated with crizotinib treatment","volume":"4","author":"Schnell","year":"2015","journal-title":"Cancer Med"},{"key":"10.1016\/j.kint.2026.01.036_bib77","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.kint.2026.01.036_bib78","first-page":"47","article-title":"Onconephrology: the intersections between the kidney and cancer","volume":"71","author":"Rosner","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.kint.2026.01.036_bib79","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"issue":"suppl","key":"10.1016\/j.kint.2026.01.036_bib80","doi-asserted-by":"crossref","first-page":"S451","DOI":"10.1016\/j.jtct.2023.12.653","article-title":"Incidence of laboratory tumor lysis syndrome in CAR T-cell recipients","volume":"30","author":"Sicre","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.kint.2026.01.036_bib81","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMra1404711","article-title":"Renal complications of hematopoietic-cell transplantation","volume":"374","author":"Hingorani","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.01.036_bib82","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.bbmt.2007.12.492","article-title":"Impact of acute kidney injury on long-term mortality after nonmyeloablative hematopoietic cell transplantation","volume":"14","author":"Parikh","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.kint.2026.01.036_bib83","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/bmt.2009.377","article-title":"A comparative assessment of the RIFLE, AKIN and conventional criteria for acute kidney injury after hematopoietic SCT","volume":"45","author":"Ando","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.kint.2026.01.036_bib84","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/sj.ki.5000055","article-title":"Acute renal failure in hematopoietic cell transplantation","volume":"69","author":"Parikh","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.01.036_bib85","doi-asserted-by":"crossref","first-page":"F418","DOI":"10.1152\/ajprenal.90319.2008","article-title":"mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes","volume":"296","author":"Vollenbr\u00f6ker","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2026.01.036_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(23)00216-4","article-title":"Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: an update","volume":"24","author":"Giraud","year":"2023","journal-title":"Lancet Oncol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826002206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826002206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:51:10Z","timestamp":1779270670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253826002206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":86,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0085253826002206"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2026.01.036","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer therapy and the kidney","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.01.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society of Nephrology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}